Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG: Oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 802-808

  Stone, Geoffrey W ^b   Barzee, Suzanne ^a   Snarsky, Victoria ^a   Santucci, Camila ^a   Tran, Brian ^a   Kornbluth, Richard S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

CD40; Dendritic cells; GITR; Mesothelioma; Monocyte macrophages; TLR3; TLR9; Tumor immunity; Vaccination

Indexed keywords

ANTIGEN; CD40 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; F4 80 ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN P 15095; PLASMID DNA; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; GENE TARGETING; MACROPHAGE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 68549110522     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a8634d     Document Type: Article

References (36)

1. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541-549. (Pubitemid 34940992)
2. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-515. (Pubitemid 38660463)
3. van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 2002;99:5561-5566.
4. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004;173: 5923-5928. (Pubitemid 39487745)
5. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T Cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-784.
6. Liu K, Idoyaga J, Charalambous A, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005;202:1507-1516. (Pubitemid 41746597)
7. Barr TA, McCormick AL, Carlring J, Health AW. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology 2003;109:87-92. (Pubitemid 36577978)
8. Friedlander PL, Delaune CL, Abadie JM, et al. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 2003;29:321-330.
9. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005;202: 919-929. (Pubitemid 41396892)
10. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-776. (Pubitemid 43090462)
11. Stone GW, Barzee S, Snarsky V, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006;80:1762-1772. (Pubitemid 43228717)
12. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+CD4+ regulatory T cells. J Exp Med 2005;202:885-891. (Pubitemid 41396888)
13. Kornbluth RS, Kee K, Richman DD. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci U S A 1998;95:5205-5210. (Pubitemid 28208576)
14. Cotten M, Baker A, Saltik M, Wagner E, Buschle M. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther 1994;1:239-246. (Pubitemid 2114964)
15. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854. (Pubitemid 27353443)
16. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881-886. (Pubitemid 23009503)
17. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001;31:3094-3100. (Pubitemid 32994561)
18. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 1998;10:1593-1598. (Pubitemid 28502373)
19. Lapointe R, Toso JF, Butts C, Young HA, Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol 2000;30:3291-3298. (Pubitemid 30846046)
20. Schulz O, Edwards AD, Schito M, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000;13:453-462. (Pubitemid 30951869)
21. Kennedy MK, Picha KS, Fanslow WC, et al. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin- 12 by mouse macrophages. Eur J Immunol 1996;26:370-378.
22. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocytederived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000;96:3499-3504.
23. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-3446. (Pubitemid 40524630)
24. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-787. (Pubitemid 29318612)
25. Hanks BA, Jiang J, Singh RA, et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005;11:130-137. (Pubitemid 40321347)
26. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483. (Pubitemid 28292196)
27. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161:2094-2098. (Pubitemid 28397017)
28. Stone GW, Barzee S, Snarsky V, et al. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 2006;13:1223-1230. (Pubitemid 46768880)
29. Anderson DG, Peng W, Akinc A, et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A 2004;101: 16028-16033. (Pubitemid 39507921)
30. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008;26:5896-5903.
31. Edwards AD, Manickasingham SP, Sporri R, et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002;169:3652-3660.
32. Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008;180:1535-1544.
33. Zheng R, Cohen PA, Paustian CA, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-4049.
34. Zhu Q, Egelston C, Vivekanandhan A, et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 2008; 105:16260-16265.
35. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-4496.
36. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gammadependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005;174:6013-6022. (Pubitemid 40663788)